Leading The Way In Pediatric Endo-Cannabinoid Medicine

Phyto Therapeutic Medicine for Inflammatory Conditions

Initial 2.2 Million Square Feet of Cultivation

Exclusive Clinically Validated Formulations

Innovation in Skin Care and Anti-Aging Systems

Relevium Enters Into Manufacturing Agreement With Bio V Pharma and Registers 400 NPN Numbers With Health Canada

MONTREAL, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today that it has registered four hundred (400) Natural Product Numbers (NPNs) with Health...

Relevium Announces Intention to Spin-Out Pediatric Cannabis Subsidiary Biocannabix

MONTREAL, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announces its intention to create a new, publicly-traded company through a spin-out of its pediatric, medical...

Relevium Announces Results of Annual Meeting of Shareholders and Updates Other Regulatory Matters

MONTREAL, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the results of the Company's annual general and special meeting (the "AGM") held...

Relevium Technologies

Relevium is a publicly traded corporation strategically focused on the expansion and acquisition of entrepreneurial brands within the health and wellness sector. Our focus is on being a trusted source of high-quality nutraceutical and CBD products.